StockData
Westlake Corp logo

Westlake Corp (WLK) stock analysis

WLKNYSEIndustrial Organic ChemicalsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/30144% above fair value
$63.88+0.72 (+1.14%)

Close on Nov 11, 2026Market cap $8.16BP/E –Yield 3.30%

StockData Score

Prices as of Nov 11, 2026How the score works

Value1Growth1Performance2Health2Dividend2

Weak8 of 30 checks passed

Westlake passes 8 of the 30 checks behind our score; 7 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
1/6
Growth
1/6
Past performance
2/6
Financial health
2/6
Dividend
2/6

What stands out

  • Dividend not cut

    The dividend per share has not fallen by more than 10% in any of the last 10 fiscal years.

  • P/B below the industry

    Westlake's price-to-book of 0.94 is below the Chemicals and Allied Products median of 1.51.

  • Gross margin improving

    Gross margin was 10.8% over the last twelve months, against 9.2% a year earlier.

  • Return on equity above the industry

    Westlake's return on equity of -4.9% is above the Chemicals and Allied Products median of -16.2%.

What to watch

  • Margin of safety under 20%

    The price is 144% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $63.88 is above our fair value estimate of $26.16.

  • Return on equity under 15%

    Return on equity was -4.9% over the last twelve months and averaged 9.8% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -2.9%, below the 10% that usually covers the cost of capital.

Valuation1/6
  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA above its 5-year median

    Westlake's EV/EBITDA of 16.3 is above its 5-year median of 6.9.

  • P/B below the industry

    Westlake's price-to-book of 0.94 is below the Chemicals and Allied Products median of 1.51.

  • Trading above fair value

    The share price of $63.88 is above our fair value estimate of $26.16.

  • Margin of safety under 20%

    The price is 144% above fair value, so there is no margin of safety.

Growth1/6
  • Revenue growing under 10% a year

    Revenue grew -10.9% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing slower than the industry

    Revenue grew -0.4% over the last twelve months; the Chemicals and Allied Products median is 3.5%.

  • Guidance issued

    The latest outlook (2026 EBITDA improvement, Feb 24, 2026) was issued for the first time, so it neither adds nor takes away points.

  • Gross margin improving

    Gross margin was 10.8% over the last twelve months, against 9.2% a year earlier.

Past performance2/6
  • Return on equity under 15%

    Return on equity was -4.9% over the last twelve months and averaged 9.8% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -2.9%, below the 10% that usually covers the cost of capital.

  • Return on equity above the industry

    Westlake's return on equity of -4.9% is above the Chemicals and Allied Products median of -16.2%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin below its 5-year average

    Net margin was -3.9% over the last twelve months, against a 5-year average of 5.3%.

  • Net margin above the industry

    Westlake's net margin of -3.9% is above the Chemicals and Allied Products median of -13.3%.

Financial health2/6
  • High debt

    Debt is 58.5% of shareholders' equity, above the 40% we consider low.

  • Debt falling against equity

    Debt to equity fell from 59.0% five years ago to 58.5%.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals 16.7% of total debt; we look for at least 20%.

  • Interest not well covered

    Operating income covers interest expense -2.0 times; we look for at least 5.

  • Short-term assets cover short-term debts

    Current assets are 2.38 times current liabilities.

  • Bankruptcy risk in the grey zone

    The Altman Z-score is 1.83; above 3 is the safe zone and below 1.8 the distress zone.

Dividend2/6
  • Pays a dividend

    Westlake paid dividends worth 3.3% of the share price over the last twelve months.

  • Yield below Treasuries

    The 3.3% yield is below the 4.4% on a 1-year Treasury.

  • Yield below the top quarter

    The top quarter of US dividend payers yield 3.8% or more; Westlake yields 3.3%.

  • Dividend not cut

    The dividend per share has not fallen by more than 10% in any of the last 10 fiscal years.

  • Earnings cover

    Needs dividends paid and net income.

  • Not covered by free cash flow

    Dividends take 2275% of free cash flow.

Scores of similar companies

Our estimate per share

$26.16

The share price is 144% above this estimate.

20%+ below
Near fair value
20%+ above
$63.88Price$26.16Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
EV/EBITDA8.7×6.9×10.4×$24.7870%
P/Bleft out, too far from the others1.5×1.5×1.5×$101.06–
Earnings power9.6% cost of equity––$29.3930%
Fair value$26.16100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/E at month end
  • Own 5-year median 12.1
  • Chemicals and Allied Products median 25.2

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$66.72M
Value traded per 1% price move
$34.73M

Downside

Medium risk

Typical loss in a bad month
22.6%
Volatility (annualized)
43%
Sharpe ratio, 1 year
-0.15
Beta to the S&P 500 (5Y)
0.94

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

7.3%−6.4 pts over 5 years

Operating margin

-14.1%−19.8 pts over 5 years

Net margin

-13.5%−17.9 pts over 5 years

See a number that looks wrong?